Remdesivir, a drug to treat COVID-19, will cost $ 2,340, Gilead Sciences announces.

0
8
Remdesivir, a drug to treat COVID-19, will cost $ 2,340, Gilead Sciences announces.


Related video that might interest you:


Replay video


FOLLOWING

FOLLOWING

Hospital reconversion helped reduce deaths from covid-19: López-Gatell (Milenio)

The price of remdesivir had already been anticipated since it became the first drug to show results for the coronavirus, which has killed more than half a million people worldwide in six months.

By Marilynn Marchione

Los Angeles, June 29 (AP) .- The drug that shortens the recovery time of patients with COVID-19 it will cost $ 2,340 for treatment for people with health insurance in the United States and other developed countries, the manufacturer reported Monday.


remdesivir


© However
remdesivir


Gilead Sciences announced that the remdesivir It will cost $ 3,120 for private insurance patients. What patients pay will depend on their insurance, income, and other factors.

“We are in unknown territory with the price of a new medicine in a pandemic,” he told The Associated Press Gilead CEO Dan O’Day.

“We had to really deviate from normal circumstances” and put a price on the drug to ensure wide access rather than just value for patients, he said.

However, the price was quickly criticized. A group of consumers considered it “outrageous” due to the amount that taxpayers invested in the development of the drug.

Treatments the company donated to the United States and other countries will run out in about a week, and prices will apply after that, O’Day said.

In 127 poor or middle-income countries, Gilead allows generic manufacturers to supply the drug; two countries already do it at a cost of about $ 600 per treatment.

The price of remdesivir had already been anticipated since it became the first drug to show results for the coronavirus, which has killed more than half a million people worldwide in six months.

The drug interferes with the coronavirus’s ability to copy its genetic material. In a study led by the US government, remdesivir cut recovery time by 31 percent: 11 days on average versus 15 days for those who receive regular care. What has not improved is survival, according to preliminary results after two weeks of follow-up. Results are expected for four weeks.






© Provided by However


The drug interferes with the coronavirus’s ability to copy its genetic material. Photo: Sebastiao Moreira, EFE

Gilead says he will have spent $ 1 billion on developing and manufacturing the drug by the end of this year.

The drug is authorized for emergency use in the United States, and Gilead has requested full approval.
Video: Together for Health has delivered 2,500 respirators for covid-19 (Millennium)

->



LEAVE A REPLY

Please enter your comment!
Please enter your name here